1 class 2 agenda start up seating chart access to course sites bb names david or will boards price increases v innovation in drug spend total us japan per capita gdp iraq pr health italy 7 discussion licensing case abgenix trends & issues current dynamics teva tentative approval for generic avandia gsk pending litigation ivax corepharma hold periostat gum disease collagenex s effort block entries schering novartis co market cancer prices post election 31 of top 50 drugs 5 11 fda delayed ruling on barr application allow plan b morning after pill be sold without a prescription german government says pharma firms still able set but that the healthcare system may not pay them germany wants restrain faux new patented don t offer additional benefits companies say there is no such thing as merck revenue flat losing 750 mln vioxx sales 4q profits down 21 legal provisions zocor non generics wholesale change plough 17 from
